On August 3 2023, AUTOLUS THERAPEUTICS ($NASDAQ:AUTL) reported a total revenue of USD 0.0 million and a net loss of USD 45.6 million for the second quarter ended June 30 2023, compared to revenue of USD 0.0 million and a net loss of USD 42.1 million in the same period last year.
On Thursday, AUTOLUS THERAPEUTICS reported its second quarter financial results with revenue of $0.0 million and net income of -$45.6 million. The stock opened at $3.0 and closed at the same price, which is 4.2% lower than the previous closing price of 3.1. The company’s CEO, Christian Itin, said that they are committed to achieving their long-term goals, despite the challenging environment. He acknowledged that the second quarter was a difficult one, but is confident that with their cost-saving measures and strategic investments in new products, the company will be able to reach its goals. Despite the challenging economic environment, Itin said that they remain focused on their mission to bring innovative treatments to patients in need and remain committed to delivering value to their shareholders.
He also mentioned that they are actively exploring collaborations and business development opportunities that could help accelerate their progress. Overall, AUTOLUS THERAPEUTICS had a tough quarter financially, but remains committed to their long-term goals and continuing to deliver value to shareholders. They are actively exploring opportunities to bring innovative treatments to patients in need and they remain hopeful for their future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Autolus Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Autolus Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Autolus Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Autolus Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has conducted an in-depth analysis of AUTOLUS THERAPEUTICS‘ fundamentals to give our clients a comprehensive understanding of this company. According to our Star Chart, AUTOLUS THERAPEUTICS is classified as a ‘cheetah’ company, which implies that it has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Therefore, investors who are looking for a higher risk-reward profile may be interested in AUTOLUS THERAPEUTICS. Additionally, GoodWhale has assigned an intermediate health score of 4/10 with regard to its cashflows and debt, suggesting that AUTOLUS THERAPEUTICS is likely to sustain future operations in times of crisis. Furthermore, our analysis revealed that AUTOLUS THERAPEUTICS is strong in asset, growth, and weak in dividend and profitability. Altogether, these observations offer a comprehensive picture of AUTOLUS THERAPEUTICS to investors. More…
Risk Rating Analysis
Star Chart Analysis
The competition between Autolus Therapeutics PLC and its competitors is heating up. The company’s most advanced product candidate, AUTO1, is a CD19-targeted CAR T cell therapy that is currently in Phase II clinical trials for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Targovax ASA, Aileron Therapeutics Inc, and Aldeyra Therapeutics Inc are all vying for a piece of the CAR T cell therapy market. Autolus is currently in the lead, but it remains to be seen how long they can hold on to their position.
– Aldeyra Therapeutics Inc ($NASDAQ:ALDX)
Aldeyra Therapeutics is a clinical-stage biotechnology company committed to developing and commercializing next-generation medicines to improve the lives of patients with autoimmune and inflammatory diseases, including dry eye disease, allergic conjunctivitis, and non-infectious uveitis. The company’s lead product candidate, reproxalap, is a novel, first-in-class small molecule that targets aldehydes. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts.
Aldeyra Therapeutics has a market cap of 323.11M as of 2022 and a Return on Equity of -22.1%. The company is focused on developing and commercializing next-generation medicines to improve the lives of patients with autoimmune and inflammatory diseases.
Targovax ASA is a clinical-stage biopharmaceutical company that focuses on the development of immuno-oncology therapies to treat solid tumors and hematological malignancies. The company’s pipeline includes TG01, a first-in-class immunotherapy targeting RAS-mutated solid tumors, and TG02, an oncolytic virus targeting mesothelioma. Targovax is headquartered in Oslo, Norway.
– Aileron Therapeutics Inc ($NASDAQ:ALRN)
Aileron Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the development of treatments for cancer. The company’s most advanced product candidate is ALRN-6924, which is in clinical development for the treatment of solid tumors. Aileron Therapeutics Inc has a market cap of 18.63M as of 2022, a Return on Equity of -56.6%. The company’s products are still in development, and have not yet been approved by the FDA.
Investors in AUTOLUS THERAPEUTICS may be concerned with its second quarter earnings report this year. The company has reported a total revenue of USD 0.0 million and a net income of USD -45.6 million for the quarter ending June 30 2023, compared to the same quarter last year where the numbers were USD 0.0 million and -42.1 million respectively. These figures have caused AUTOLUS THERAPEUTICS shares to drop on August 3 2023. Investors should take this into consideration when evaluating their investments in the company.